China's medical products administrator approved Guangdong Hybribio Biotech (SHE:300639) subsidiary Guangzhou Kaipu Pharmaceutical Technology's medical device registration for its SOX1 and PAX1 gene methylation detection kit.
The kits are used to diagnose 12 high-risk human papillomavirus (HPV) genotypes in females, according to a Wednesday filing with the Shenzhen Stock Exchange.
The permit is valid for five years.
Price (RMB): ¥5.28, Change: ¥+0.020, Percent Change: +0.38%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments